Peter Krajci

  • Medical Advisor; MD, PhD

Medical Advisor at Section of Emergency Addiction Services and Detoxification.


Publications 2024

Havig SM, Berg-Pedersen RM, Krabseth HM, Müller LD, Haugaa K, Zare HK, Gjesdal K, Krajci P, Opdal MS (2024)
Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients
Basic Clin Pharmacol Toxicol, 134 (4), 519-530
DOI 10.1111/bcpt.13982, PubMed 38308508

Publications 2022

Edvardsen HME, Aamodt C, Bogstrand ST, Krajci P, Vindenes V, Rognli EB (2022)
Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
Br J Clin Pharmacol, 88 (10), 4494-4504
DOI 10.1111/bcp.15365, PubMed 35470456

Publications 2020

Krackhardt F, Kočka V, Waliszewski M, Toušek P, Janek B, Trenčan M, Krajči P, Lozano F, Roman KG, Otaegui I, Del Blanco BG, Del Olmo VV, Nofrerías EF, Wachowiak L, Heang TM, Ahn TH, Jeong MH, Jung BC, Han KR, Piot C, Sebagh L, Rischner J, Pansieri M, Leschke M (2020)
Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice
Medicine (Baltimore), 99 (8), e19119
DOI 10.1097/MD.0000000000019119, PubMed 32080086

Krackhardt F, Waliszewski M, Wan Ahmad WA, Kočka V, Toušek P, Janek B, Trenčan M, Krajči P, Lozano F, Garcia-San Roman K, Otaegui Irurueta I, Garcia Del Blanco B, Wachowiak L, Vilalta Del Olmo V, Fernandez Nofrerías E, Ho Jeong M, Jung BC, Han KR, Piot C, Sebagh L, Rischner J, Pansieri M, Leschke M, Ahn TH (2020)
Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes
PLoS One, 15 (1), e0226606
DOI 10.1371/journal.pone.0226606, PubMed 31929543

Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, Tanum L (2020)
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Addiction, 116 (8), 2084-2093
DOI 10.1111/add.15378, PubMed 33338285

Publications 2019

Latif ZE, Šaltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, Sharma-Haase K, Tanum L (2019)
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
JAMA Psychiatry, 76 (2), 127-134
DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
Am J Addict, 28 (2), 77-85
DOI 10.1111/ajad.12859, PubMed 30701613

Solli KK, Kunoe N, Latif ZE, Sharma-Haase K, Opheim A, Krajci P, Gaulen Z, Šaltytė Benth J, Tanum L (2019)
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
Eur Addict Res, 25 (6), 303-309
DOI 10.1159/000501931, PubMed 31340204

Publications 2018

Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P (2018)
The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
Eur Addict Res, 24 (6), 286-292
DOI 10.1159/000495188, PubMed 30466108

Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, Tanum L, Kunoe N (2018)
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
Addiction, 113 (10), 1840-1849
DOI 10.1111/add.14278, PubMed 29806872

Publications 2017

Krajči P, Kirnbauer R, Parajka J, Schöber J, Blöschl G (2017)
The Kühtai data set: 25 years of lysimetric, snow pillow, and meteorological measurements
Water Resour Res, 53 (6), 5158-5165
DOI 10.1002/2017WR020445, PubMed 28931957

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N (2017)
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
JAMA Psychiatry, 74 (12), 1197-1205
DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469

Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B (2017)
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
DOI 10.1097/MEG.0000000000000962, PubMed 28914697

Publications 2016

Henriksen K, Waal H, Krajci P (2016)
Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27

Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N (2016)
Buprenorphine dosing choices in specific populations: review of expert opinion
Expert Opin Pharmacother, 17 (13), 1727-31
DOI 10.1080/14656566.2016.1209486, PubMed 27376622

Publications 2015

Alho H, D'Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, Roncero C, Somaini L, Wright N, Littlewood R (2015)
The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33

Alho H, Jansen J, Krajci P, Littlewood R, Runarsdottir V, Nyberg F (2015)
Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49

Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
Clin Ther, 37 (7), 1594-9
DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997

Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, McKeganey N, Littlewood R, Krajci P, Alho H, D'Agnone O (2015)
The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
Eur Addict Res, 22 (2), 99-106
DOI 10.1159/000438988, PubMed 26426530

Wright N, D'Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, Roncero C, Somaini L, Maremmani I (2015)
Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
J Public Health (Oxf), 38 (3), e368-e374
DOI 10.1093/pubmed/fdv150, PubMed 26508767

Publications 2005

Vermund H, Krajci P, Eide TJ, Winther F (2005)
Histopathological grading of laryngectomy specimens
APMIS, 113 (7-8), 473-88
DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817

Publications 2004

Vermund H, Krajci P, Eide TJ, Winther F (2004)
Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
Acta Oncol, 43 (1), 98-107
DOI 10.1080/02841860310020366, PubMed 15068327

Publications 2002

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2000

Wiatrowska B, Krajci P, Berner A (2000)
[Pseudo-Meigs' syndrome]
Tidsskr Nor Laegeforen, 120 (3), 364-6
PubMed 10827530

Publications 1999

Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P (1999)
Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
J Exp Med, 190 (7), 915-22
DOI 10.1084/jem.190.7.915, PubMed 10510081

Nilsen EM, Johansen FE, Kvale D, Krajci P, Brandtzaeg P (1999)
Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
Eur J Immunol, 29 (1), 168-79
DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098

Norderhaug IN, Johansen FE, Krajci P, Brandtzaeg P (1999)
Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
Eur J Immunol, 29 (10), 3401-9
DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352

Publications 1998

Johansen FE, Bosløven BA, Krajci P, Brandtzaeg P (1998)
A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
Eur J Immunol, 28 (4), 1161-71
DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355

Publications 1997

Winberg JO, Hammami-Hauasli N, Nilssen O, Anton-Lamprecht I, Naylor SL, Kerbacher K, Zimmermann M, Krajci P, Gedde-Dahl T, Bruckner-Tuderman L (1997)
Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
Hum Mol Genet, 6 (7), 1125-35
DOI 10.1093/hmg/6.7.1125, PubMed 9215684

Publications 1996

Krajci P, Meling GI, Andersen SN, Hofstad B, Vatn MH, Rognum TO, Brandtzaeg P (1996)
Secretory component mRNA and protein expression in colorectal adenomas and carcinomas
Br J Cancer, 73 (12), 1503-10
DOI 10.1038/bjc.1996.284, PubMed 8664120

Publications 1995

Brandtzaeg P, Krajci P (1995)
The enterocyte and immunoglobulin transport
Dyn.Nutr.Res., 4, 1-17

Kamei M, Iwase T, Krajci P, Brandtzaeg P, Moro I (1995)
Antibody production to secretory component (SC) using recombinant SC fragment
Adv Exp Med Biol, 371A, 633-5
DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006

Krajci P, Kvale D, Brandtzaeg P (1995)
Cloning, chromosomal localization, and linkage analysis of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Adv Exp Med Biol, 371A, 617-23
DOI 10.1007/978-1-4615-1941-6_130, PubMed 8526003

Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
DNA Cell Biol, 14 (3), 251-6
DOI 10.1089/dna.1995.14.251, PubMed 7880445

Moro I, Takahashi T, Iwase T, Asano M, Takenouchi N, Nishimura S, Kudo I, Krajci P, Brandtzaeg P, Moldoveanu Z (1995)
Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
Adv Exp Med Biol, 371A, 175-82
DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901

Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, Brandtzaeg P (1995)
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
Gut, 37 (6), 766-76
DOI 10.1136/gut.37.6.766, PubMed 8537046

Norstein J, Krajci P, Bergan A, Geiran O (1995)
Intestinal perforation after ingestion of a blister-wrapped tablet
Lancet, 346 (8985), 1308
DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762

Publications 1993

Krajci P, Taskén K, Kvale D, Brandtzaeg P (1993)
Interferon-gamma stimulation of messenger RNA for human secretory component (poly-Ig receptor) depends on continuous intermediate protein synthesis
Scand J Immunol, 37 (2), 251-6
DOI 10.1111/j.1365-3083.1993.tb01763.x, PubMed 8434236

Publications 1992

Brandtzaeg P, Halstensen TS, Huitfeldt HS, Krajci P, Kvale D, Scott H, Thrane PS (1992)
Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
Ann N Y Acad Sci, 664, 157-79
DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647

Ann.NY Acad.Sci., 664, 157-179
DOI 10.1111/j.1749-6632.1992.tb39758.x

Krajči P (1992)
Molecular biology of human secretory component (the poly-Ig receptor: characterization of cDNA and genomic clones, chromosomal assignment, and mRNA expression
Laboratory for Immunohistochemistry and Immunopathology (LIIPAT), Institute of Pathology, University of Oslo, The National Hospital, Rikshospitalet, Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 930575830, ISBN 82-7633-017-7

Krajci P, Gedde-Dahl T, Høyheim B, Rogde S, Olaisen B, Brandtzaeg P (1992)
The gene encoding human transmembrane secretory component (locus PIGR) is linked to D1S58 on chromosome 1
Hum Genet, 90 (3), 215-9
DOI 10.1007/BF00220065, PubMed 1487233

Krajci P, Kvale D, Taskén K, Brandtzaeg P (1992)
Molecular cloning and exon-intron mapping of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Eur J Immunol, 22 (9), 2309-15
DOI 10.1002/eji.1830220920, PubMed 1355431

Kvale D, Krajci P, Brandtzaeg P (1992)
Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
Scand J Immunol, 35 (6), 669-76
DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489

Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992)
Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
Genomics, 14 (1), 63-9
DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799

Publications 1991

Krajci P, Grzeschik KH, Geurts van Kessel AH, Olaisen B, Brandtzaeg P (1991)
The human transmembrane secretory component (poly-Ig receptor): molecular cloning, restriction fragment length polymorphism and chromosomal sublocalization
Hum Genet, 87 (6), 642-8
DOI 10.1007/BF00201717, PubMed 1682231

Publications 1989

Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989)
Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
Gastroenterology, 97 (6), 1562-84
DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725

Krajci P, Solberg R, Sandberg M, Oyen O, Jahnsen T, Brandtzaeg P (1989)
Molecular cloning of the human transmembrane secretory component (poly-Ig receptor) and its mRNA expression in human tissues
Biochem Biophys Res Commun, 158 (3), 783-9
DOI 10.1016/0006-291x(89)92790-3, PubMed 2920039

Publications 1986

Iversen OH, Krajci P, Thoresen G (1986)
The fate of epidermal colcemid-arrested mitoses
Virchows Arch B Cell Pathol Incl Mol Pathol, 51 (2), 115-26
DOI 10.1007/BF02899022, PubMed 2873676

Publications 1980

Krajči P, Thoresen G (1980)
Veneriske sykdommer og samfunnsendringer: "sammenhengen mellom veneriske sykdommer og strukturelle endringer i samfunnsforhold i Norge i perioden 1860 til 1900"
In Spesialoppgave, Universitetet i Oslo, Oslo, 36 s.
BIBSYS 051913356

Page visits: 4334